Related Experiment Video

Updated: Jun 21, 2026

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
08:56

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes

Published on: October 10, 2025

Generation of a patient-derived iPSC line from a clinically diagnosed MELAS case carrying the mtDNA m.3243A > G

Gautam Sharma1, Abhay Srivastava1, Cheryl Rockman-Greenberg2

  • 1Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Regenerative Medicine Program, Department of Physiology and Pathophysiology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Canada.

Stem Cell Research
|June 19, 2026
PubMed

Insights

Researchers successfully created patient-specific induced pluripotent stem cells (iPSCs) from a MELAS patient. These iPSCs offer a new model for studying mitochondrial diseases and testing potential therapies.

Area of Science:

  • Biomedical research
  • Genetics
  • Stem cell biology

Background:

  • Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) is a severe multisystemic mitochondrial disorder.
  • The common cause is the m.3243A>G mutation in the mitochondrial DNA (mtDNA) MT-TL1 gene.

Purpose of the Study:

  • To generate a patient-specific induced pluripotent stem cell (iPSC) line from a MELAS patient.
  • To establish a valuable research platform for investigating MELAS pathophysiology.
  • To facilitate screening of therapeutic interventions for mitochondrial dysfunction.

Main Methods:

  • Reprogramming of peripheral blood mononuclear cells (PBMCs) from a MELAS patient.
  • Generation of induced pluripotent stem cells (iPSCs).

Main Results:

  • Successful generation of a patient-specific iPSC line from a MELAS patient.
  • The iPSC line carries the characteristic MELAS mutation, providing a genetically relevant model.

Conclusions:

  • Patient-derived iPSCs are a powerful tool for MELAS research.
  • This iPSC line enables in vitro studies of mitochondrial disease mechanisms.
  • The model can accelerate the development of targeted therapies for MELAS.

More Related Videos

An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model06:05

An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model

Published on: March 9, 2022

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing07:24

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

Published on: February 10, 2023

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...